Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma

September 18th 2025

Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

Dr Mouhieddine on the Potential Predictive Role of Ferritin Levels and ALC in Bispecific Antibody–Treated Multiple Myeloma

September 17th 2025

Tarek Mouhieddine, MD, discusses the predictive role of ferritin levels and ALC in patients with multiple myeloma receiving bispecific antibodies.

ISB 2001 Shows Favorable Safety Profile and Antitumor Activity in R/R Multiple Myeloma

September 17th 2025

ISB 2001 had a manageable safety profile and induced deep, durable responses at active doses in patients with relapsed/refractory multiple myeloma.

Dr Raab on Updated Findings With Teclistamab-Based Induction in Newly Diagnosed Multiple Myeloma

September 17th 2025

Marc S. Raab, MD, PhD, discusses the efficacy of teclistamab-based induction in patients with newly diagnosed multiple myeloma.

Cevostamab Plus Pomalidomide/Dexamethasone Is Safe, Active in R/R Myeloma

September 17th 2025

The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma

September 17th 2025

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

FDA Approves 2 Denosumab Biosimilars in High Fracture Risk Populations, Including in Breast and Prostate Cancer

September 17th 2025

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Histone Modification–Related Gene Signature Shows Prognostic Value in Multiple Myeloma

September 17th 2025

An HMR risk signature predicted outcomes in multiple myeloma, linked with genomic instability, immune microenvironment, and drug sensitivity.

Expert-Backed Roadmap Guides Outpatient Bispecific Antibody Use in Myeloma

September 14th 2025

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting

September 11th 2025

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

Emerging Bispecifics and Trispecifics and Addressing Unmet Needs in R/R MM

September 11th 2025

Panelists discuss how trispecific antibodies targeting multiple antigens show promise for preventing antigen escape, while identifying ultrahigh-risk patients, frail patients, optimal treatment duration, and therapy access as key unmet needs.

Dr Popat on the Rationale for Assessing JNJ-5322 in Relapsed/Refractory Myeloma

September 8th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the mechanism of action and the impetus for assessing JNJ-5322 in relapsed/refractory multiple myeloma.

SC Daratumumab Prolongs PFS in High-Risk Smoldering Myeloma

September 5th 2025

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

Addressing Challenges to Bispecific Integration Across Practice Settings in MM

September 4th 2025

Panelists discuss how academic centers can partner with community practices through early engagement, initial step-up dosing support, and education to overcome barriers to bispecific adoption.

EHA 2025 Data Updates: RedirecTT-1 -Talquetamab + Teclistamab

September 4th 2025

Panelists discuss how the RedirecTT-1 combination of talquetamab and teclistamab shows promising efficacy in extramedullary disease (EMD) with a 79% overall response rate, though with increased infectious complications.

Dr Raza on Unmet Needs in R/R Myeloma With Extramedullary Disease

September 2nd 2025

Shahzad Raza, MD, highlights the challenges associated with managing relapsed/refractory multiple myeloma with extramedullary disease.

FDA Approves New Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

September 2nd 2025

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Diagnosed Myeloma

August 29th 2025

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

Clinical Strategies for Managing GPRC5D-Related Adverse Events

August 28th 2025

Panelists discuss how to identify and manage GPRC5D-related toxicities, including skin rash, nail problems, and dysgeusia, emphasizing patient education, nutritional support, and dose modification strategies.